Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

verfasst von: Robert Zeiser, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.
Literatur
1.
2.
Zurück zum Zitat Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;5:389–96.CrossRef Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;5:389–96.CrossRef
3.
Zurück zum Zitat Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.CrossRefPubMed Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med. 1999;341:1837–8.CrossRefPubMed
4.
Zurück zum Zitat Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003;62:87–94.CrossRefPubMed Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003;62:87–94.CrossRefPubMed
5.
Zurück zum Zitat Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.PubMed Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.PubMed
6.
Zurück zum Zitat Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRefPubMed Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.CrossRefPubMed
7.
Zurück zum Zitat Silvestris N, Leone B, Numico G, et al. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005;69:273–82.CrossRefPubMed Silvestris N, Leone B, Numico G, et al. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005;69:273–82.CrossRefPubMed
8.
Zurück zum Zitat McArdle PA, Canna K, McMillan DC, et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541–3.CrossRefPubMed McArdle PA, Canna K, McMillan DC, et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541–3.CrossRefPubMed
9.
Zurück zum Zitat Elkord E, Rowbottom AW, Kynaston H, et al. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin Immunol. 2006;120:91–8.CrossRefPubMed Elkord E, Rowbottom AW, Kynaston H, et al. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin Immunol. 2006;120:91–8.CrossRefPubMed
10.
Zurück zum Zitat Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173:6098–108.PubMed Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173:6098–108.PubMed
11.
Zurück zum Zitat Miller AM, Lundberg K, Ozenci V, et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398–405.PubMed Miller AM, Lundberg K, Ozenci V, et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398–405.PubMed
12.
Zurück zum Zitat Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.CrossRefPubMed Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254–61.CrossRefPubMed
13.
Zurück zum Zitat Zheng X, Gao JX, Zhang H, et al. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol. 2002;169:4761–9.PubMed Zheng X, Gao JX, Zhang H, et al. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol. 2002;169:4761–9.PubMed
14.
Zurück zum Zitat Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res. 2005;65:2947–55.CrossRefPubMed Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res. 2005;65:2947–55.CrossRefPubMed
15.
Zurück zum Zitat Dürr C, Pfeifer D, Claus R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70:10170–81.CrossRefPubMed Dürr C, Pfeifer D, Claus R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70:10170–81.CrossRefPubMed
16.
Zurück zum Zitat Schellhammer PE, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol. 2003;23:47–9.CrossRef Schellhammer PE, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol. 2003;23:47–9.CrossRef
17.
Zurück zum Zitat Michiels A, Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 2005;12:772–82.CrossRefPubMed Michiels A, Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 2005;12:772–82.CrossRefPubMed
18.
Zurück zum Zitat Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 2005;12:699–707.CrossRefPubMed Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 2005;12:699–707.CrossRefPubMed
19.
Zurück zum Zitat Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigen peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998;114:166–72.CrossRefPubMed Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigen peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998;114:166–72.CrossRefPubMed
20.
Zurück zum Zitat Alexander RB, Brady F, Leffell MS. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology. 1998;51:150–7.CrossRefPubMed Alexander RB, Brady F, Leffell MS. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology. 1998;51:150–7.CrossRefPubMed
21.
Zurück zum Zitat Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic Tlymphocytes specific for peptides derived from prostata-specific antigen. JNCI. 1997;89:293–300.CrossRefPubMed Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic Tlymphocytes specific for peptides derived from prostata-specific antigen. JNCI. 1997;89:293–300.CrossRefPubMed
22.
Zurück zum Zitat Thomas-Kaskel AK, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006;119:2428–34.CrossRefPubMed Thomas-Kaskel AK, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006;119:2428–34.CrossRefPubMed
23.
Zurück zum Zitat Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012;8:1–8.CrossRef Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012;8:1–8.CrossRef
24.
Zurück zum Zitat Sims RB. Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J Cancer. 2011;2:357–9.CrossRefPubMed Sims RB. Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J Cancer. 2011;2:357–9.CrossRefPubMed
25.
Zurück zum Zitat Tang S, Moore ML, Grayson JM, et al. Increased CD8+ T cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res. 2012;72:1975–85.CrossRefPubMed Tang S, Moore ML, Grayson JM, et al. Increased CD8+ T cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res. 2012;72:1975–85.CrossRefPubMed
26.
Zurück zum Zitat Akins EJ, Moore ML, Tang S, et al. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res. 2010;70:3473–82.CrossRefPubMed Akins EJ, Moore ML, Tang S, et al. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res. 2010;70:3473–82.CrossRefPubMed
27.
Zurück zum Zitat Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol. 2011;186:5162–72.CrossRefPubMed Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol. 2011;186:5162–72.CrossRefPubMed
28.
Zurück zum Zitat Radojevic K, Arsenovic-Ranin N, Kosec D, et al. Neonatal castration affects in trathymic kinetics of T cell differentiation and the spleen T-cell level. J Endocrinol. 2007;192:669–82.CrossRefPubMed Radojevic K, Arsenovic-Ranin N, Kosec D, et al. Neonatal castration affects in trathymic kinetics of T cell differentiation and the spleen T-cell level. J Endocrinol. 2007;192:669–82.CrossRefPubMed
29.
Zurück zum Zitat Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009;69:571–84.CrossRefPubMed Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009;69:571–84.CrossRefPubMed
30.
Zurück zum Zitat Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate. 2010;70:1002–11.PubMed Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate. 2010;70:1002–11.PubMed
31.
Zurück zum Zitat Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–49.CrossRefPubMed Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–49.CrossRefPubMed
32.
Zurück zum Zitat Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430–9.CrossRefPubMed Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430–9.CrossRefPubMed
33.
Zurück zum Zitat van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–17.CrossRefPubMed van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–17.CrossRefPubMed
34.
Zurück zum Zitat Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501–8.CrossRefPubMed Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:501–8.CrossRefPubMed
35.
Zurück zum Zitat Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849–59.CrossRefPubMed Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849–59.CrossRefPubMed
36.
Zurück zum Zitat Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380–6.PubMed Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380–6.PubMed
37.
Zurück zum Zitat Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.CrossRefPubMed Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.CrossRefPubMed
38.
Zurück zum Zitat Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010;16:5269–76.CrossRefPubMed Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010;16:5269–76.CrossRefPubMed
Metadaten
Titel
Immunotherapeutic approaches targeting prostate cancer and its microenvironment
verfasst von
Robert Zeiser, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0021-4

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe